Subscribe: MedWorm: Prostate Cancer
http://www.medworm.com/rss/medicalfeeds/cancers/Prostate-Cancer.xml
Preview: MedWorm: Prostate Cancer

MedWorm: Prostate Cancer



MedWorm.com provides a medical RSS filtering service. Over 7000 RSS medical sources are combined and output via different filters. This feed contains the latest news and research in the Prostate Cancer category.



Last Build Date: Tue, 29 Mar 2016 16:46:38 +0100

 



A phase 2 clinical trial of everolimus plus bicalutamide for castration‐resistant prostate cancer

Tue, 29 Mar 2016 07:07:45 +0100

CONCLUSIONSThe combination of bicalutamide and everolimus has encouraging efficacy in men with bicalutamide‐naive CRPC, thus warranting further investigation. A substantial number of patients experienced everolimus‐related toxicity. Cancer 2016. © 2016 American Cancer Society. (Source: Cancer)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Bayer Receives Approval for Xofigo® in Japan (for specialized target groups only)

Tue, 29 Mar 2016 06:30:00 +0100

Marketing authorization granted for the treatment of castration-resistant prostate cancer patients with bone metastases (Source: Bayer Company News)



For prostate cancer, more radiation may not improve survival

Tue, 29 Mar 2016 04:00:00 +0100

(Thomas Jefferson University) Increasing the total dose of radiation to patients with non-metastatic prostate cancer does not improve their long-term outcomes, according to a new study. (Source: EurekAlert! - Cancer)



U.S. lawmakers want health agencies to lower prostate cancer drug cost

Tue, 29 Mar 2016 02:22:41 +0100

(Reuters) - A group of lawmakers is calling on the National Institutes of Health and Department of Health and Human Services to step in and reduce the cost of Medivation Inc's and Astellas Pharma Inc's prostate cancer drug Xtandi. (Source: Reuters: Health)



Two cups of coffee could reduce likelihood of developing prostate cancer

Tue, 29 Mar 2016 00:01:17 +0100

New research based on more than 550,000 men worldwide shows that the likelihood of developing the disease decreases with coffee. (Source: the Mail online | Health)



A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy

Mon, 28 Mar 2016 22:00:00 +0100

Publication date: May 2016 Source:Urology Case Reports, Volume 6 Author(s): Jeffrey J. Tosoian, Diane K. Reyes, Michael A. Gorin, Steven Hortopan, Alan W. Partin, Kenneth J. Pienta, Ashley E. Ross, Edward M. Schaeffer The bone marrow microenvironment represents a “metastatic niche” in which prostate cancer cells may persist and evade cytotoxic therapy. In order to study the biology of prostate cancer dissemination, we have established a safe and efficient method for performing pubic bone marrow aspiration at the time of radical prostatectomy. We herein describe our experience with this technique. (Source: Urology Case Reports)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Surgical Management of Ureteral Strictures Arising From Radiotherapy for Prostate Cancer

Mon, 28 Mar 2016 22:00:00 +0100

We describe four cases of these ureteral strictures emphasizing pre-operative factors that may have contributed to development of the strictures, their ultimate surgical management, and the patients' short-term outcomes. (Source: Urology Case Reports)



Mp40-20 relationship between non-tumor prostate volume and risk of positive surgical margin in organ confined prostate cancer

Mon, 28 Mar 2016 19:24:11 +0100

It is not uncommon for the prostate cancer to form multiple satellite foci with main index tumor which has kept uniform method for approximation of tumor volume a difficult task. This has been suggested as one reason behind the controversy over association of tumor volume with biochemical recurrence and treatment failure. We have quantified non-tumor prostate volume to analyze its correlation with occurrence of positive surgical margin which is renown as strong predictor of biochemical recurrence. (Source: The Journal of Urology)



Mp40-19 a new subclassification system for decision making with intermediate risk prostate cancer patients treated by radical prostatectomy: a multicenter study

Mon, 28 Mar 2016 19:24:11 +0100

Intermediate risk group based on the preoperative d’Amico system remains heterogenous with different patterns of prognosis. Improved stratification is need to optimize treatment and monitoring strategy. (Source: The Journal of Urology)



Mp40-18 long-term oncological outcomes following radical prostatectomy for clinical t1a and t1b prostate cancer

Mon, 28 Mar 2016 19:24:11 +0100

Prostate cancer (PCa) is incidentally found in 4–16% of patients surgically treated for benign prostatic hyperplasia. It is staged as clinical T1a or T1b based on the percentage of tumor in the specimen: (Source: The Journal of Urology)



Mp40-17 impact of regional hypothermia on urinary continence during rarp: results from a double-blind randomized control trial

Mon, 28 Mar 2016 19:24:11 +0100

We performed a multi-institutional double-blind randomized control trial to assess if regional hypothermia via reduce inflammation could improve urinary continence using an endorectal cooling balloon (ECB) during robotic-assisted radical prostatectomy (RARP). (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp40-16 risk factors of biochemical recurrence in locally advanced prostate cancer patients with preoperative gleason grade of 4 or 5 after robot-assisted radical prostatectomy

Mon, 28 Mar 2016 19:24:11 +0100

Controversy remains over the issue concerning if there are survival benefits performing radical prostatectomy for the patients diagnosed to be at locally advanced stage on imaging studies. It is generally perceived that tumors containing Gleason grade 4 or 5 patterns on the biopsy are associated with treatment failure. We have investigated on risk factors of biochemical recurrence after the robot-assisted radical prostatectomy for the locally advanced prostate cancer patients with tumors including Gleason 4 or 5 patterns. (Source: The Journal of Urology)



Mp40-15 oncologic outcomes after robotic-assisted laparoscopic vs retropubic radical prostatectomy for high-risk prostate cancer in korean men using k-cap registry

Mon, 28 Mar 2016 19:24:11 +0100

This study compared a cohort of high-risk patients undergoing open ORP and RARP at three institutions (K-CaP registry). (Source: The Journal of Urology)



Mp40-14 predictors of extraprostatic extension after radical prostatectomy in a contemporary cohort of men biopsied with an extended biopsy scheme

Mon, 28 Mar 2016 19:24:11 +0100

When performing a radical prostatectomy (RP), the surgeon is conflicted by the concurrent but antagonizing goals of prostate cancer (CaP) control and nerve bundle preservation. We reviewed preoperative variables predictive of extraprostatic extension (EPE) in a contemporary cohort of men diagnosed with extended biopsy schemes. (Source: The Journal of Urology)



Mp40-13 prognostic factors and oncologic outcomes after robot-assisted radical prostatectomy in pt3b prostate cancer

Mon, 28 Mar 2016 19:24:11 +0100

Seminal vesicle invasion (SVI) after radical prostatectomy (RP) in patients with prostate cancer (PCa) is a known predictor of poor survival. The oncological outcome after robot-assisted radical prostatectomy (RARP) is not fully investigated. We addressed the long-term outcomes of pT3b prostate cancer treated with RARP, and prognostic factors for oncologic outcomes. (Source: The Journal of Urology)



Mp40-12 long-term oncological outcomes of salvage radical prostatectomy for radio-recurrent/persistent prostate cancer after radiation therapy.

Mon, 28 Mar 2016 19:24:11 +0100

Radiation therapy is a commonly used primary treatment for clinically localized prostate cancer (PCa). The majority of patients who fail primary radiation therapy will receive palliative hormonal therapy. However, a number of patients will have persistent/recurrent cancer in the prostate only and will benefit from salvage extirpative or ablative local therapy. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp40-11 the role of robot-assisted radical prostatectomy and extended pelvic lymph node dissection in patients with locally advanced prostate cancer: results from a multi-institutional series

Mon, 28 Mar 2016 19:24:11 +0100

Previous studies demonstrated that robot-assisted radical prostatectomy (RARP) might represent an oncologically safe option in patients with high-risk prostate cancer (PCa). However, none of these investigations focused on men with locally advanced disease (i.e., clinical stage T3 or greater). The aim of our study was to assess the safety and effectiveness of RARP in patients with locally advanced PCa treated at two high-volume European institutions. (Source: The Journal of Urology)



Mp40-10 comparison of positive surgical margin rates in prostate cancer: open versus robot assisted laparoscopic radical prostatectomy

Mon, 28 Mar 2016 19:24:11 +0100

We compared positive surgical margin (PSM) rates for patients with prostate cancer who underwent open retropubic radical (RRP) and robotic assisted laparoscopic (RALP) prostatectomy at a single institution. (Source: The Journal of Urology)



Mp40-09 impact of nerve sparing on postoperative continence following robot assisted radical prostatectomy: a propensity score matched study

Mon, 28 Mar 2016 19:24:11 +0100

We evaluated the impact of nerve sparing during robot assisted radical prostatectomy (RARP) on postoperative continence outcomes in a single surgeon, single center propensity score matched study. (Source: The Journal of Urology)



Mp40-08 influence of pathologist on positive surgical margins following radical prostatectomy: analysis of 3,557 cases

Mon, 28 Mar 2016 19:24:11 +0100

A positive surgical margin (PSM) following radical prostatectomy (RP) for prostate cancer (PCa) is associated with an increased risk of biochemical recurrence. Studies have found inter-observer concordance for margins to be approximately 87-89%. We sought to examine whether the individual pathologist is an independent predictor of PSMs. (Source: The Journal of Urology)



Mp40-07 long-term follow-up data after radical prostatectomy: determining when to stop psa monitoring

Mon, 28 Mar 2016 19:24:11 +0100

In this study, we analyzed our long-term follow-up data after radical prostatectomy, and determined how long we should follow the patients whose PSA level continuously remains low. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp40-06 longitudinal investigation on predictors of continence outcomes in patients undergoing robot-assisted radical prostatectomy

Mon, 28 Mar 2016 19:24:11 +0100

Incontinence is a common complication that occurs after radical prostatectomy. Various factors are reported to be associated with the recovery of continence after surgery. However, there are few reports regarding longitudinal data. Herein, we investigated predictors of continence outcomes at 3, 6, and 12 months after robot assisted radical prostatectomy. (Source: The Journal of Urology)



Mp40-05 evaluation of outcomes of salvage robotic prostatectomy: single surgeon experience

Mon, 28 Mar 2016 19:24:11 +0100

There is a significant cohort of patients who experience recurrent prostate cancer after primary ablative therapy. Salvage robot assisted radical prostatectomy (sRARP) represents a feasible treatment option in these cases. The purpose of the study is to examine the functional and biochemical outcomes in a large series of sRARP performed by a single surgeon (VRP). (Source: The Journal of Urology)



Mp40-04 minimally invasive salvage prostatectomy after primary radiation or ablation treatment: complications, functional and long-term oncological outcomes

Mon, 28 Mar 2016 19:24:11 +0100

We aimed to analyze the oncologic, functional and morbidity outcomes of minimally invasive salvage prostatectomy (MISP) after primary radiation or ablation treatment for prostate cancer at a tertiary referral institution. (Source: The Journal of Urology)



Mp40-03 extended vs. limited pelvic lymph node dissection during bilateral nerve-sparing radical prostatectomy and its effect on continence and erectile function recovery: long-term results and trifecta rates of a comparative analysis

Mon, 28 Mar 2016 19:24:11 +0100

To assess continence and erectile function (EF) recovery of extended pelvic lymph node dissection (ePLND) vs. limited PLND (lPLND) after bilateral nerve-sparing radical prostatectomy (BNSRP). (Source: The Journal of Urology)



Mp40-02 short-term results of extended pelvic lymphadenectomy during laparoscopic radical prostatectomy in 1,000 consecutive patients.

Mon, 28 Mar 2016 19:24:11 +0100

Pelvic lymphadenectomy (PLND) is the most reliable method of detecting lymph node (LN) involvement (LNI) by prostate cancer. Extended PLND (ePLND) is recommended for patients with a probability of LNI of 5% or above as evidence shows that removal of a greater number of pelvic LNs improves detection of LNI, allows stratification of affected patients to receive adjuvant therapy and may improve oncological outcomes. However, there is some suggestion that it is also associated with a greater operating time and a higher complication rate. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp40-01 who benefits from robot-assisted radical prostatectomy in terms of functional outcome?

Mon, 28 Mar 2016 19:24:11 +0100

This study compared urinary and sexual function outcomes between RARP and RRP, to identify those patients who would benefit from RARP. (Source: The Journal of Urology)



Mp39-20 are there any appropriate criteria for recommending prostate biopsy in patients over 75 years old?

Mon, 28 Mar 2016 19:24:11 +0100

In this study, we investigated the diagnostic value of prostate-specific antigen (PSA) and its multiple factors in men over 75 years of age to avoid overdiagnosis and reduce unnecessary biopsy procedures. (Source: The Journal of Urology)



Mp39-19 prostate cancer detection with digital rectal exam in the prostate lung colorectal and ovarian (plco) cancer screening trial

Mon, 28 Mar 2016 19:24:11 +0100

There has been great controversy regarding prostate cancer screening with prostate specific antigen (PSA) due to conflicting results from two large randomized trials. However, the contemporary role of digital rectal exam (DRE) for screening has been largely overlooked. This is particularly salient given the recent decline in PSA and possibly overall prostate cancer screening. We sought to evaluate the prognostic significance of suspicious DRE in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Trial in which men were randomized to annual screening with PSA and DRE or usual care. (Source: The Journal of Urology)



Mp39-18 higher frequency of germline brca1 and brca2 mutations in african american prostate cancer

Mon, 28 Mar 2016 19:24:11 +0100

BRCA1 and BRCA2 tumor suppressor proteins play a critical role in protecting genome integrity by participating in the repair of damaged DNA and have been implicated in breast, ovarian and other cancers. Mutations in BRCA2 have been linked to a higher risk of prostate cancer (CaP), and high frequency of BRCA2 and BRCA1 gene alterations were recently reported in metastatic castration resistant CaP specimens. Mutations in BRCA2 vary in racial and ethnic groups including African American (AA) and Caucasian American (CA) populations. (Source: The Journal of Urology)



Mp39-17 poor performance of the zaytoun prostate biopsy nomogram in multiple external validation cohorts

Mon, 28 Mar 2016 19:24:11 +0100

Most prostate cancer prediction models (“nomograms”) are developed using a single cohort, often at a single hospital, and are never externally validated. Using four independent cohorts, we evaluated the discrimination, calibration, and net benefit of two nomograms that predict high grade (Gleason≥7) and any grade cancer after prostate biopsy among undiagnosed men without a prior negative biopsy. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp39-16 detecting high grade cancer and reducing prostate biopsy among plco participants using a pre-specified statistical model based on levels of four kallikrein markers and microseminoprotein-beta in blood

Mon, 28 Mar 2016 19:24:11 +0100

In this study we assess use of this panel of markers (4K) and MSP among men of African American (AA) and European ancestry in PLCO. (Source: The Journal of Urology)



Mp39-15 screening for prostate cancer: results from the swiss section of the erspc (aarau)

Mon, 28 Mar 2016 19:24:11 +0100

This study aims to investigate the influence of the PSA based screening on the PCa specific mortality. The study setting is the prospective randomized population based screening trial with the primary hypothesis that screening can significantly reduce PCa specific mortality by at least 25%. (Source: The Journal of Urology)



Mp39-14 impact of the 2012 united states preventive services task force recommendation against prostate specific antigen screening on prostate cancer risk group stratification

Mon, 28 Mar 2016 19:24:11 +0100

We examined the changes in prostate cancer (PCa) stage at diagnosis before and after the USPSTF recommendation. (Source: The Journal of Urology)



Mp39-13 baseline prostate-specific antigen (psa) levels in midlife predict total and aggressive prostate cancer in african-american men

Mon, 28 Mar 2016 19:24:11 +0100

Prostate specific antigen (PSA) level in midlife predicts prostate cancer (PCa) mortality in Caucasian populations. It is poorly studied whether PSA measured during midlife predicts aggressive PCa among African-American men, a group for which PCa disparities exist. (Source: The Journal of Urology)



Mp39-12 gleason misclassification in different active surveillance protocols: correlation between fusion biopsies mri-ultrasound fusion guided biopsy and final radical prostatectomy specimen

Mon, 28 Mar 2016 19:24:11 +0100

Biopsy Gleason is the main tool to stratify prostate cancer patients (PCa) into risk groups and advise treatment options such as active surveillance (AS) in low-risk patients. Most AS protocols cover low risk patients and only a limited number of protocols include patients harbouring Gleason 4 pattern. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp39-11 baseline psa before age 60 as a predictor of important prostate cancer diagnosis and prostate cancer-specific mortality in the intervention arm of the prostate, lung, colorectal and ovarian trial

Mon, 28 Mar 2016 19:24:11 +0100

The Prostate, Lung, Colorectal and Ovarian (PLCO) study evaluated the impact of organized annual PSA screening on prostate cancer (PCa) incidence and PCa-specific mortality. We sought to determine the future risk of clinically significant PCa diagnosis based on a baseline PSA (bPSA) measurement in younger men at study entry. (Source: The Journal of Urology)



Mp39-10 serum insulin-like growth factor-1 (igf-1) was a valuable biomarker to predict the high grade prostate cancer in final pathology in patients who had low to intermediate disease on biopsy.

Mon, 28 Mar 2016 19:24:11 +0100

High level of Insulin-like growth factor-1 (IGF-1) was reported to be positively associated with low grade prostate cancer but not to high grade disease. We evaluated the role of preoperative serum IGF-1 level in predicting high grade disease (Gleason score [GS] ≥ 8) in the prostatectomy specimen in patients with low (GS ≤ 6) or intermediate grade (GS = 7) disease on biopsy. (Source: The Journal of Urology)



Mp39-09 properties of the four kallikrein panel for prediction of prostate biopsy outcome in men with high psa (10-25 ng /ml)

Mon, 28 Mar 2016 19:24:11 +0100

A statistical model based on a panel of four kallikrein markers (PSA, free PSA, intact PSA and hK2) has been shown to predict high-grade cancer on prostate biopsy in close to 15,000 patients in 11 different European cohorts. The panel was recently validated in a prospective US trial, and is available clinically as the 4Kscore. Unlike several other reflex tests, the kallikrein panel is not restricted to patients in the diagnostic “grey zone” (such as PSA 4-10 ng / mL, negative DRE). However, properties of the panel for men with higher PSA have not been reported. (Source: The Journal of Urology)



Mp39-08 clinical utility of an epigenetic assay to reduce unnecessary repeat prostate biopsies

Mon, 28 Mar 2016 19:24:11 +0100

Management of men at risk of harboring prostate cancer (PCa), but with a cancer-negative index biopsy remains difficult. An epigenetic assay assessing PCa-associated DNA-methylation of GSTP1, RASSF1 and APC in histologically negative biopsies has shown to improve the negative predictive value (NPV) relative to standard of care (SOC) yielding a NPV of 90% for all PCa and 96% for high-grade (Gleason score (GS) ≥ 7) PCa. The primary goal was to ascertain the rate of repeat biopsy in relation to the epigenetic test and how this changed the management of patients. (Source: The Journal of Urology)



Mp39-07 the 4kscore can potentially reduce unnecessary prostate biopsies in men with suspicious psa in a screening population

Mon, 28 Mar 2016 19:24:11 +0100

The U.S. Preventive Services Task Force currently recommends against prostate-specific antigen (PSA)-based screening for prostate cancer. Hence, there is a need for more specific tests to avoid unnecessary prostate biopsies and overtreatment of clinically insignificant cancer. The 4Kscore is a new commercially available molecular diagnostic test which predicts risk for clinically significant prostate cancer on prostate biopsy. Our objective was to examine potential correlation between the 4Kscore and other parameters in a screening population and ability to reduce the number of prostate biopsies indicated compared to PSA alone. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp39-06 impact of guidelines on prostate cancer screening in a population-based setting, 2000-2014: preliminary results from the first aua data grant

Mon, 28 Mar 2016 19:24:11 +0100

This study evaluates temporal trends in the use of prostate specific antigen (PSA) tests among men ages 40-80 years at two sites in the NCI-funded Cancer Research Network following the publication of prostate cancer (PCa) screening trial results in 2009 and changes to the US Preventive Services Task Force (USPSTF) guidelines in 2012. (Source: The Journal of Urology)



Mp39-05 swiss prostate-check - a population based risk-calculator for next generation prostate cancer screening

Mon, 28 Mar 2016 19:24:11 +0100

Population based organized screening is superior to opportunistic screening in prostate cancer (PCa). Both are impaired by the high prevalence of latent clinically irrelevant PCa underlining the need for a smarter, risk-based screening process in order to detect relevant PCa and reduce overdiagnosis. The aim of the study was to provide a prognostic and diagnostic PCa risk calculator based on PSA, free-to-total PSA-ratio (f/t PSA-ratio), digital rectal examination (DRE), prostate volume (PV), age and family history (FH) in a prospective, PSA-driven population based screening trial. (Source: The Journal of Urology)



Mp39-04 initial prostate cancer detection before and after united states preventive services task force recommendation on prostate cancer screening

Mon, 28 Mar 2016 19:24:11 +0100

Because of mixed data regarding the effects of USPSTF recommendation against prostate cancer screening on prostate cancer detection in the literature and an apparent difference we recognized in pathology reporting occurring in our urology practice, we were prompted to review prostate biopsy (PBx) results before and after that recommendation which was published in 2012. (Source: The Journal of Urology)



Mp39-03 decreasing screening efficacy with increasing age: results from a population-based screening trial - swiss erspc (aarau)

Mon, 28 Mar 2016 19:24:11 +0100

There is limited evidence for screening efficacy in older men. The aim of the current work was to investigate whether screening efficacy at age ≥ 67 was changed in men participating in the Swiss arm of the ERSPC. (Source: The Journal of Urology)



Mp39-02 development and validation of a risk prediction model for prostate cancer diagnosis within a statewide quality improvement collaborative

Mon, 28 Mar 2016 19:24:11 +0100

The Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) is one of several publicly available tools to predict prostate cancer (CaP) risk prior to prostate needle biopsy (PNB). We explored whether more contemporary PNB registry data from a statewide quality improvement collaborative can be used to create a risk prediction model that better predicts cancer risk. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp39-01 use of psa screening guidelines among primary care physicians

Mon, 28 Mar 2016 19:24:11 +0100

Widespread implementation of prostate specific antigen (PSA) based prostate cancer screening has resulted in the detection of both clinically significant and insignificant cancer. In 2012 the United States Preventive Services Task Force (USPSTF) recommended that screening should not be offered to men unless there was shared decision making. Other guidelines have recommended PSA screening but for only limited circumstances. As 90% of the PSA testing ordered in the United States is by primary care providers (PCP), we sought to determine their opinions about several aspects of prostate cancer and PSA. (Source: The Journal of Urology)



Fri-03 the history of prostate cancer from antiquity: review of paleopathological studies

Mon, 28 Mar 2016 19:24:11 +0100

We present a historical review of the prostate cancer in antiquity based on paleopathological findings. (Source: The Journal of Urology)



Mp50-04 neoadjuvant androgen deprivation in primarily inoperable prostate cancer: consecutive assessment of peri-and postoperative outcomes

Mon, 28 Mar 2016 19:24:10 +0100

The combination of a neoadjuvant androgen deprivation therapy (ADT) and radical prostatectomy (RP) in very high risk prostate cancer (PCa) is not covered by any guideline. Thus only a few retrospective studies reported on this topic. Herein we analysed a series of patients who received neoadjuvant ADT due to initially inoperable prostate cancer. (Source: The Journal of Urology)



Mp50-03 salvage radical prostatectomy complications and functional outcomes: open versus robotic procedures.

Mon, 28 Mar 2016 19:24:10 +0100

To report and compare open (O) versus robotic (R) salvage radical prostatectomy (sRP) functional outcomes and complications. (Source: The Journal of Urology)



Mp50-02 does the number of lymph nodes sampled during radical prostatectomy impact risk of biochemical recurrence in patients with seminal vesicle invasion?

Mon, 28 Mar 2016 19:24:10 +0100

Seminal vesicle invasion (SVI) is a poor prognostic indicator associated with an increased risk of biochemical recurrence (BCR) and prostate cancer-specific mortality. Since patients with this pathologic finding are closely followed and often offered adjuvant therapy, any modification in surgical technique that may reduce the risk of BCR in patients with SVI would be of great importance. An extended pelvic lymph node dissection during radical prostatectomy (RP) when indicated is a surgical technique that facilitates accurate identification of nodal metastases and furthermore may confer a survival benefit. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp50-01 survival analysis of patients with node positive prostate cancer after radical prostatectomy comparing observation vs. adjuvant androgen deprivation therapy alone vs. adjuvant androgen deprivation plus external beam radiation therapy.

Mon, 28 Mar 2016 19:24:10 +0100

The presence of lymph node metastasis (LNM) after radical prostatectomy (RP) is associated with poor survival. The optimal management of patients with LNM remains undefined. The aim of this study is to evaluate the association between three different management strategies and survival in prostate cancer with LNM after RP. (Source: The Journal of Urology)



Pd28-12 a phase 1 study of a third-generation oncolytic hsv-1 g47Δ in patients with castration resistant prostate cancer

Mon, 28 Mar 2016 19:24:10 +0100

Oncolytic herpes simplex viruses type 1 (HSV-1) is an attractive therapeutic agent for treating cancer due to its capacity to selectively replicate in cancer cells, kill them, and spread their progeny to surrounding cancer cells. Recently, FDA approved IMLYGIC™ (Talimogene laherparepvec) as the first oncolytic virus drug in developed countries. IMLYGIC is a second-generation oncolytic HSV-1 that showed a higher durable response rate and a better overall survival in the group of advanced malignant melanoma patients than the control group. (Source: The Journal of Urology)



Pd28-11 novel drugs for targeting histone deacetylase inhibitor to cells containing androgen receptors: analysis of in vivo effectiveness against human prostate cancer.

Mon, 28 Mar 2016 19:24:10 +0100

The objective of this study was to test the effectiveness of these new drugs in an in vivo model of human prostate cancer and compare to HDACi and antiandrogens alone. (Source: The Journal of Urology)



Pd28-10 combinatorial therapeutic approaches with pd-1 inhibition in prostate cancer

Mon, 28 Mar 2016 19:24:10 +0100

Checkpoint blockade targeting PD-1 or CTLA-4 works by fundamentally different mechanisms (with CTLA-4 inhibition acting at secondary lymphoid organs for activation of naïve T cells, and PD-1 interactions being regulated at the tissue / tumor level to effect T cells already exposed to antigen). The efficacy and toxicity profile of anti-PD-1/PD-L1 and anti-CTLA-4 therapies also differ greatly, with PD-1/PD-L1 therapy having relatively low toxicity. In both humans and animal models, PD-1 directed therapy for prostate cancer had not been shown to be efficacious. (Source: The Journal of Urology)



Pd28-09 abnormal her2 and her3 signalling in prostate cancer: potentials for clinical application.

Mon, 28 Mar 2016 19:24:10 +0100

HER family members (EGFR, HER2, HER3 and HER4) have been associated with the development of castrate-resistant prostate cancer. Previous research has focussed on targeting EGFR and HER2 receptors, however the role of HER3 in driving PI3K/Akt signalling and mediating drug resistance has shifted the attention towards this signalling partner. The use of pan-inhibitors targeting multiple members of the HER receptor family represents an attractive therapeutic approach in prostate cancer. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Pd28-08 radiotherapy for prostate in men with metastatic prostate cancer: a propensity-score matching analysis

Mon, 28 Mar 2016 19:24:10 +0100

In this study, we retrospectively investigate the efficacy of prostate radiotherapy for patients diagnosed with mPCa using propensity-score matching analysis. (Source: The Journal of Urology)



Pd28-07 assessment of the rate of adherence to international guidelines of androgen deprivation therapy with external beam radiation therapy- a population-based study

Mon, 28 Mar 2016 19:24:10 +0100

The objective of the current study was to examine the rate of adherence to these guidelines within a large-scale population-based data repository. We hypothesized near-perfect guideline adherence. (Source: The Journal of Urology)



Pd28-06 survival outcomes in octogenarian and nonagenarian patients treated with first-line androgen deprivation therapy for localized prostate cancer

Mon, 28 Mar 2016 19:24:10 +0100

Use of primary androgen deprivation therapy (PADT) is common in elderly men with localized prostate cancer (PCa), despite absence of guideline recommendations. Herein, we examined survival patterns of octo- and nonagenarian men with localized PCa exposed to PADT, to assess whether their life expectancy warrants ADT use. (Source: The Journal of Urology)



Pd28-05 factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer

Mon, 28 Mar 2016 19:24:10 +0100

Bone metastases frequently cause skeletal related events (SRE) in patients with metastatic castration-resistant prostate cancer (CRPC). However, there is a paucity of data identifying which factors are associated with SRE for patients with bone metastatic CRPC (mCRPC). Thus, the objective of this study was to assess predictors of SRE using characteristics commonly available in the medical chart at the time of bone mCRPC diagnosis. (Source: The Journal of Urology)



Pd28-04 detection of androgen receptor variant 7 (ar-v7) in whole blood rna of metastatic castration-resistant prostate cancer (mcrpc) patients treated with abiraterone acetate (abi)

Mon, 28 Mar 2016 19:24:10 +0100

Expression of androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) has been associated with resistance to ABI and enzalutamide (ENZ) (Antonarakis et al. N Engl J Med 2014). We have developed a RT-PCR assay that is neither time sensitive nor requires CTC enrichment for detection of prostate cancer (PCa)-associated transcripts in whole blood. Using this assay, our aim was to correlate AR-V7 expression with outcomes on ABI. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Pd28-03 compliance with evidence based bone health management in men on chronic adt: opportunities for improvement

Mon, 28 Mar 2016 19:24:10 +0100

In this study we report compliance with these evidence based guidelines. (Source: The Journal of Urology)



Pd28-02 an ipod-guided slow breathing intervention to control hot flashes in advanced prostate cancer patients on hormone therapy

Mon, 28 Mar 2016 19:24:10 +0100

The purpose of this study is to determine the feasibility and efficacy of a breathing technique, guided by an iPod Touch® application, to manage hot flashes among prostate cancer (PC) survivors after experiencing a rising PSA. Androgen deprivation therapy (ADT) is considered first-line treatment for this patient population. Although effective in slowing the rise in PSA, ADT has side effects, such as vasomotor symptoms (VS; also known as hot flashes). Up to 50% of men report VS severe enough to require treatment. (Source: The Journal of Urology)



Pd28-01 testosterone lowering, psa response and quality of life in patients with advanced hormone sensitive prostate cancer receiving tak-385, an oral gnrh antagonist: phase 2 interim analysis

Mon, 28 Mar 2016 19:24:10 +0100

TAK-385 is an investigational, oral, non-peptide GnRH antagonist in late phase 2 evaluation for the management of hormone sensitive prostate cancer (HSPC). Two trials are ongoing: TAK-385 120 mg daily (QD) vs degarelix for patients (pts) requiring 6-mos neoadjuvant/adjuvant to EBRT (NCT02135445) and continuous TAK-385 80 or 120 mg QD vs leuprorelin (LEU) for advanced PC (relapse post local treatment or M1; NCT02083185; reported here). (Source: The Journal of Urology)



Pd26-12 complications associated with transrectal and transperineal prostate mapping biopsy

Mon, 28 Mar 2016 19:24:10 +0100

To evaluate incidence of complications in men undergoing transrectal (TRUS) and transperineal mapping biopsy (TPMB). (Source: The Journal of Urology)



Pd26-11 biopsy patterns of patients with hgpin or asap in the era of active surveillance

Mon, 28 Mar 2016 19:24:10 +0100

To investigate the practice patterns of prostate biopsy in patients with high grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP). (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Pd26-10 incidence of clinically-significant prostate cancer after a diagnosis of atypical small acinar proliferation (asap), prostatic intraepithelial neoplasia (pin), or benign tissue

Mon, 28 Mar 2016 19:24:10 +0100

Repeat prostate biopsy after an initial biopsy that fails to demonstrate cancer may reveal ′clinically-significant′ or ′insignificant′ cancer (based upon Gleason score, volume of disease, and PSA). Here, we assess the incidence of clinically significant and insignificant prostate cancer after an initial biopsy revealed either ASAP, PIN, or benign tissue. (Source: The Journal of Urology)



Pd26-09 doppler ultrasonography-guided pelvic plexus block before needle biopsy of the prostate: a single center, prospective, randomized controlled trial

Mon, 28 Mar 2016 19:24:10 +0100

Periprostatic nerve block (PNB) is considered to be the ‘gold standard’ for decreasing the pain from needle biopsy of prostate. However, PNB has not been found to be totally satisfactory and can not block a few nerve fibers that supply the superolateral and anterior part of the prostate. The purpose of the present study was to assess the efficacy of pelvic plexus block (PPB) in reducing pain during TRUS–guided biopsy compared with PNB. (Source: The Journal of Urology)



Pd26-08 improved tissue yield and prostate cancer detection of a novel biopsy preservation system

Mon, 28 Mar 2016 19:24:10 +0100

Current handling of prostate biopsy cores has many flaws. Fragmentation, loss of orientation and length reduction are just few factors that may reduce cancer detection or obscure the tumor location. The SmartBxTM(SBx)(UC-care medical system) offers a semi-automated download of cores, while preserving its configuration and orientation as on the needle, onto a designated cassette which then goes a routine pathology lab processing. Our objectives were to assess this system against a routine download in maintaining tissue length and integrity, and examine its effect on cancer detection. (Source: The Journal of Urology)



Pd26-07 does digital rectal exam affect the 4kscore test for aggressive prostate cancer?

Mon, 28 Mar 2016 19:24:10 +0100

The 4Kscore is a new commercially available molecular diagnostic test which predicts risk for aggressive, clinically significant prostate cancer on prostate biopsy. The 4Kscore is currently restricted to patients who have not had a digital rectal exam (DRE) in the previous 96 hours, owing to prior mixed data suggesting that prostate specific antigen (PSA) isoforms may increase by a statistically significant--if not necessarily clinically significant--amount shortly after DRE. Our objective was to determine if 4Kscore test results are affected by a preceding DRE. (Source: The Journal of Urology)



Pd26-06 changes in prostate health index (phi) over time

Mon, 28 Mar 2016 19:24:10 +0100

The prostate health index (PHI) was recently approved by the FDA as an aid in the early detection of prostate cancer (PCa). PHI scores are currently stratified into four risk categories. There is limited information on repeated PHI measurements and changes in risk categories over time in such patients. We studied serial PHI results over 18 months in 90 patients presenting for evaluation of an elevated PSA of ≥2ng/mL. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Pd26-05 diagnostic accuracy of prostate health index for aggressive prostate cancer. an institutional validation study.

Mon, 28 Mar 2016 19:24:10 +0100

The objective of this study has been to validate Prostate Health Index (PHI) as a marker of aggressive PCa in one academic institution. (Source: The Journal of Urology)



Pd26-04 racial and ethnic variation in time to prostate biopsy after an elevated psa blood level screening result

Mon, 28 Mar 2016 19:24:10 +0100

To examine the racial and ethnic variation in time to prostate biopsy after an elevated prostate-specific antigen (PSA) blood level screening result. (Source: The Journal of Urology)



Pd26-03 prostate biopsy in the era of contemporary uspstf guidelines

Mon, 28 Mar 2016 19:24:10 +0100

In 2012, the United States Preventative Services Task Force (USPSTF) recommended against routine prostate specific antigen (PSA) screening for early detection of prostate cancer. The Brooklyn Veterans Hospital patient population consists of >50% African American (AA) men, who are felt to be at higher risk for development of prostate cancer, as well as the development of more aggressive disease than the general population. Therefore, we sought to analyze whether these recommendations have impacted the patterns of care and results of biopsies in our high-risk patient population. (Source: The Journal of Urology)



Pd26-02 using a prebiopsy checklist to understand risk factors associated with infection-related hospitalization following prostate biopsy

Mon, 28 Mar 2016 19:24:10 +0100

We examined determinants of hospitalization using a specifically designed prebiopsy checklist implemented in the Michigan Urological Surgery Improvement Collaborative (MUSIC). (Source: The Journal of Urology)



Pd26-01 changes in clinico-pathological characteristics at prostate cancer diagnosis detected on prostate biopsies in danish men from 1995 to 2011

Mon, 28 Mar 2016 19:24:10 +0100

The incidence of prostate cancer (PCa) in Denmark has increased dramatically during the past two decades. PCa now accounts for 25% of all male cancers in Denmark, a change that parallels an increased use of PSA testing among healthy men. We hypothesized that this development has had a tremendous impact on clinico-pathological parameters at diagnosis of PCa over time, due to lead time bias. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp47-02 sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 hypro trial

Mon, 28 Mar 2016 19:24:10 +0100

Oncologic outcomes following hypofractionated radiotherapy (19x 3.4 Gy) for prostate cancer are comparable to conventionally fractionated treatment (39x 2 Gy). Hypofractionated radiotherapy is delivered in less fractions, offering economic and logistical advantages. The effects of hypofractionation on sexual function, however, are unknown. Here, we present results on sexual function from the Dutch randomized HYPRO trial. (Source: The Journal of Urology)



Mp46-19 castration-resistant prostate cancer patients in quebec: medication use in the last year of life

Mon, 28 Mar 2016 19:24:10 +0100

In the last decade, significant advances have been made in the field of prostate cancer, including many innovative drugs for advanced prostate cancer. The current management of metastatic castration-resistant prostate cancer (mCRPC) has become very complex. The study objective was to describe medication use in the last year of life of patients dying of prostate cancer in Quebec. (Source: The Journal of Urology)



Mp46-18 use of abiraterone acetate in the management of castration-resistant prostate cancer: a real-life cost effectiveness study

Mon, 28 Mar 2016 19:24:10 +0100

This study evaluated the cost-effectiveness of abiraterone in the management of mCRPC in a real-life setting in Quebec. (Source: The Journal of Urology)



Mp46-17 treatment variation in economically disadvantaged men with advanced prostate cancer: comparing public and private providers

Mon, 28 Mar 2016 19:24:10 +0100

Although most newly diagnosed cases of prostate cancer are clinically localized, 16% present with advanced disease. We compared treatment types and healthcare utilization among men with advanced prostate cancer treated by private versus public providers. (Source: The Journal of Urology)



Mp46-15 cost effectiveness of mri before prostate biopsy

Mon, 28 Mar 2016 19:24:10 +0100

We examined the cost effectiveness of MRI in the management of prostate cancer, and discuss the implications of this analysis. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Mp46-13 risk of hospitalization following primary treatment for prostate cancer

Mon, 28 Mar 2016 19:24:10 +0100

Surgery and radiotherapy remain the primary treatments for prostate cancer with comparable oncologic outcomes and variable side effect profiles. Research regarding readmission rates following treatment is lacking. We sought to compare the risk of hospitalization between patients following surgery versus radiotherapy as primary definitive treatment. (Source: The Journal of Urology)



Mp45-04 paternally expressed gene-10 promotes cell growth and invasion of bladder cancer

Mon, 28 Mar 2016 19:24:10 +0100

We have recently identified that paternally expressed gene-10 (PEG10) promotes cell cycle progression in the context of TP53 and RB1 loss in neuroendocrine prostate cancer. Based on the evidence that TP53 mutations and RB1 inactivation are more prevalent in muscle invasive bladder cancer (MIBC), it is possible that PEG10 may contribute to the progression and prognosis of MIBC. To test this hypothesis, we characterized PEG10 function in bladder cancer and evaluated if PEG10 can be a novel therapeutic target for these cancers. (Source: The Journal of Urology)



Pd25-10 a statewide intervention to reduce the use of low value imaging among men with newly-diagnosed prostate cancer.

Mon, 28 Mar 2016 19:24:10 +0100

Based on analysis of our initial data and a literature review, the Michigan Urological Surgery Improvement Collaborative (MUSIC) felt that expansion of the population that does not need imaging beyond just low-risk prostate cancer patients was appropriate. We therefore developed and disseminated criteria that both minimize unnecessary imaging and are extremely unlikely to omit a positive study. (Source: The Journal of Urology)



Mp42-20 incidental prostate cancer diagnosed at holmium laser enucleation of prostate - review of patient outcomes

Mon, 28 Mar 2016 19:24:10 +0100

We reviewed the initial oncologic outcomes of prostate cancer incidentally diagnosed at the time of holmium laser enucleation of prostate (HoLEP) for the treatment of benign prostatic hypertrophy. (Source: The Journal of Urology)



Pd32-12 long-term follow-up of circulating tumor cells as predictors for survival in men treated with abiraterone acetate for castration resistant prostate cancer following chemotherapy

Mon, 28 Mar 2016 19:24:09 +0100

Circulating tumor cells (CTCs) are established biomarkers to predict response to chemotherapy (CTX) in metastatic castration resistant prostate cancer (mCRPC). Recently, a biomarker panel comprising CTC also demonstrated to be predictive for survival in men treated with Abiraterone Acetate (AA) after chemotherapy in the COU-AA-301 pivotal trial., As validation studies are underway, we present long-term data of our sub-analysis of the German named patient program (nPP). (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Pd32-11 gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients

Mon, 28 Mar 2016 19:24:09 +0100

Characterization of gene expression in bone metastasis is critical to the identification of therapeutic targets and prognostic/predictive biomarkers in metastatic castrate-resistant prostate cancer (mCRPC). Although bone marrow tissue can be obtained for molecular analysis, bone marrow biopsy (BMBx) is relatively invasive. In contrast, circulating tumor cells (CTCs) can be obtained by simple blood draw, and in mCRPC, CTCs likely emanate from bone metastases. Herein, we wished to establish a sensitive method to analyze gene expression in BMBxs and CTCs and to determine whether potential biomarkers present in bone lesions are mirrored in CTCs. (Source: The Journal of Urology)



Pd32-10 phosphorylation of ampkα at ser-485/491 is associated with metastasis and castration-resistance in prostate cancer: a clinical study

Mon, 28 Mar 2016 19:24:09 +0100

We have previously shown that AMPKα activity is significantly inhibited by Ser-485/491 phosphorylation in cell culture and in vivo models of metastatic and castration-resistant prostate cancer (PCa). To determine potential translatability, we investigated Ser-485/491 phosphorylation status in clinical PCa specimens and its correlation with metastasis and progression to castration-resistance. (Source: The Journal of Urology)



Pd32-09 combination effect of therapies targeting the pi3k-mtor and ar signaling pathways in prostate cancer

Mon, 28 Mar 2016 19:24:09 +0100

Several drugs targeting the androgen-signaling pathway or PI3K-AKT-mTOR pathway are in clinical trails for prostate cancer (PCa). Despite promise drugs such as RAD001 have not shown dramatic affectivity in clinical trials. This is perhaps due to a feedback loop that exits between the AR- and PI3K-AKT pathways. Combining drugs is an effective way of overcoming signaling cross talks, increasing efficacy and reducing resistance development. Towards this, a systematic and detailed analysis of the combined effects of the drugs targeting the 2 pathways needs to be carried out. (Source: The Journal of Urology)



Pd32-08 synergistic anticancer effect of combination treatment with mek inhibitor and pi3k /mtor dual inhibitor in castration-resistant prostate cancer in vivo and ex vivo

Mon, 28 Mar 2016 19:24:09 +0100

This study investigated whether monotherapy with either the dual PI3K/mTOR inhibitor GSK2126458 or the MEK inhibitor AZD6244 might activate other pathways and whether the combination of both drugs might be synergistic in PTEN-deletion/mutated prostate cancer in vivo and ex vivo. (Source: The Journal of Urology)



Pd32-07 galeterone shows anti-tumor activity in multiple pre-clinical models that express androgen receptor splice variants, supporting correlative patient data seen in armor2

Mon, 28 Mar 2016 19:24:09 +0100

Galeterone is a selective, multitargeted, small molecule that disrupts androgen signaling at multiple points in the pathway by enhancing androgen receptor (AR) degradation, inhibiting androgen biosynthesis, and antagonizing androgen binding to the AR. AR splice variant-7 (AR-V7) is a truncated, constitutively active splice variant of the AR that lacks the ligand binding domain (LBD), and has been implicated in castration resistant prostate cancer (CRPC) progression. AR-V7 expression is detected in approximately 12-26% of men with metastatic CRPC (mCRPC) prior to second-generation anti-androgens or chemotherapy, and AR-V7 expression has been clinically associated with resistance to enzalutamide (Xtandi) and abiraterone (Zytiga). (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Pd32-06 long-term safety and antitumor activity of odm-201 in chemotherapy and cyp17-inhibitor naÏve patients from the arades and the arafor trials

Mon, 28 Mar 2016 19:24:09 +0100

ODM-201 is a new generation oral androgen receptor inhibitor demonstrating tolerability and antineoplastic efficacy in metastatic castration resistant prostate cancer (mCRPC) patients. Here we report the combined long-term safety and antitumor activity of ODM-201 in ARADES (phase 1-2, NCT01317641, NCT01429064) and ARAFOR (phase 1 bioavailability, NCT01784757) trials in chemotherapy- and CYP17-inhibitor-naive patients. (Source: The Journal of Urology)



Pd32-05 phase i clinical study on the combination therapy of chp-ny-eso-1 cancer vaccine and mis416 for the treatment of patients with ny-eso-1 expressing refractory urothelial cancer or castration-resistant prostate cancer

Mon, 28 Mar 2016 19:24:09 +0100

NY-ESO-1 antigen is a cancer-testis antigen that is exclusively expressed in several types of cancer, aside from expression in the normal testis and placenta. This antigen is considered an ideal target for cancer immunotherapy. Cholesteryl pullulan (CHP) is a novel antigen delivery system. Complexes of CHP and NY-ESO-1 antigen (CHP-NY-ESO-1) present multiple epitope peptides to both the MHC class I and class II pathways. MIS416 is a non-toxic microparticle adjuvant that activates immune responses via NOD-2 and TLR9 pathways. (Source: The Journal of Urology)



Pd32-04 phase i/ii clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of hvj-e to castration resistant prostate cancer patients

Mon, 28 Mar 2016 19:24:09 +0100

Inactivated Sendai virus particles (hemagglutinating virus of Japan envelope; HVJ-E) has a novel antitumor effect: HVJ-E fused to prostate cancer cells via cell surface receptor, causing apoptosis of prostate cancer cells in vitro and in vivo. HVJ-E also induces anti-tumor immunity by activating natural killer (NK) cells and cytotoxic T cells as well as suppressing regulatory T cells in vivo. We conducted an open-label, single-arm Phase I/II clinical trial in castration resistant prostate cancer (CRPC) patients to determine the safety and efficacy of intratumoral and subcutaneous injection of HVJ-E. (Source: The Journal of Urology)



Pd32-03 a phase 2 open-label trial of gtx-758 in men with castration-resistant prostate cancer, final analysis of the primary endpoint

Mon, 28 Mar 2016 19:24:09 +0100

Recently approved agents that target the androgen receptor pathway emphasize the importance of the persistent activity of the androgen receptor pathway in castration-resistant prostate cancer (CRPC). This raises the possibility that agents with distinct mechanisms of action may add value. GTx-758 is a selective ERα agonist that can increase SHBG and therefore reduce biologically active testosterone (T) levels. Reported here are the results, including the final primary endpoint analysis, from the 250 mg daily GTx-758 cohort of a Phase 2 clinical trial in men on LHRH agonists that developed CRPC. (Source: The Journal of Urology)



Pd32-02 novel pi3k/p110beta-specific inhibitors eliminate enzalutamide resistance in prostate cancer

Mon, 28 Mar 2016 19:24:09 +0100

We and others have demonstrated that the class IA PI3K isoform p110beta is critical in prostate cancer development and progression, indicating p110beta as a bona fide target for prostate cancer therapy. Our recent work consistently shows that prostate cancer cell-specific delivery of nano-micellar TGX221 completely blocked prostate cancer growth in vivo, suggesting that TGX221-based therapy is feasible for further development. Unfortunately, the small chemical TGX221 is not soluble in water, hampering its clinical development. (Source: The Journal of Urology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.




Pd32-01 pre-clinical rationale for combination pi3k and brd4 inhibition in advanced prostate cancer

Mon, 28 Mar 2016 19:24:09 +0100

This study details our pre-clinical evaluation of AZD8186, a novel β- and δ- selective PI3K small molecule inhibitor in prostate cancer models. We and others have recently noted the role of the oncogene myc as a mechanism of resistance to monotherapy treatment with PI3K/Akt inhibitors. Therefore, we further evaluated co-targeting strategies against both the PI3K/Akt pathway and the epigenetic reader protein BRD4. (Source: The Journal of Urology)



Mp57-20 patterns of clinical recurrence and predictors of systemic progression of prostate cancer patients with psa persistence after radical prostatectomy

Mon, 28 Mar 2016 19:24:09 +0100

Previous studies demonstrated that Prostate Cancer (PCa) patients who experience PSA persistence after radical prostatectomy (RP) are at increased risk of clinical progression and death. We hypothesized that the outcomes of patients with PSA persistence after RP are heterogeneous and that not all patients would ultimately experience adverse outcomes (Source: The Journal of Urology)



Mp57-19 the influence of board certification on outcomes after radical prostatectomy

Mon, 28 Mar 2016 19:24:09 +0100

This study examined the effect of board certification on RP outcomes. (Source: The Journal of Urology)



Mp57-18 expression of steroid hormone receptors in residual cancer and stromal cells after neoadjuvant chemohormonal therapy with docetaxal for high-risk localized prostate cancer

Mon, 28 Mar 2016 19:24:09 +0100

In this study, we investigated SHR expressions in human PCa tissues in patients who underwent radical prostatectomy (RP) with and without neoadjuvant chemohormonal therapy. (Source: The Journal of Urology)